2Bastion Y, Blay JY, Divine M, et al. Elderly patients with aggressivenon-hodgkin's lymphoma:disease presentation to treatment, and survival a grouped'e rude des lymphomas de l' adulte study on 453 patients older than 69 years[J].J Clin Oncol, 1997,15(8):2945- 2953.
1Tone H,Kurebe M,Takeuchi T,et al. Experimental studies on(2"R)-4'-0-Tetrahydropyranyladriamycin (THP) [ A ]. In: Kuemmerle HP.Advanced in experimental and clinical chemotherapy. 15th International Congress of chemotherapy. Landsbeg/Lech: Ecomed, 1998. 1-9.
2Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen(CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med, 1993,328: 1002-1006.
3Wakui A, Yokoyama M, Konno K, et al. Phase I trial of 4'-O-tetrahydropyranyl-doxorubicin (THP) -a multi-institutional cooperative study. Gan To Kagaku Ryoho,1985,12:118-124.
4Takagi T, Sakai C, Oguro M, et al. Combination chemotherapy with pirarubicin ( THP ), cyclophosphamide, vincristine, and prednisolone ( VEP-THP therapy) in the treatment of non-Hodgkin's lymphoma.Oncology,1990,47:25-28.
5Rossini F,Terruzzi E,Perego D,et al. Long-term follow-up of patients with intermediate or high-grade non-Hodgkin lymphoma treated with a combination of cyclophosphamide, epirubicin, vincristine, and prednisone. Cancer, 2004,100:350-355.
6Chim CS, Kwong YL, Lie AK, et al. CEOP treatment results and validity of the International Prognostic Index in Chinese patients with aggressive non-Hodgkin's lymphoma. Hematol Oncol, 1998 , 16:117-123.
